These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 2563434

  • 1. Uncoated versus coated 5-aminosalicylic acid in Crohn's disease.
    Bossi A, Giuliani GE, Del Poggio P, Fenili D, Ragaini S.
    Lancet; 1989 Feb 04; 1(8632):276. PubMed ID: 2563434
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease.
    Hardy JG, Healey JN, Reynolds JR.
    Aliment Pharmacol Ther; 1987 Aug 04; 1(4):273-80. PubMed ID: 2979672
    [Abstract] [Full Text] [Related]

  • 4. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. International Mesalazine Study Group.
    Aliment Pharmacol Ther; 1990 Feb 04; 4(1):55-64. PubMed ID: 2104074
    [Abstract] [Full Text] [Related]

  • 5. Experience with Eudragit-S-coated mesalamine (Asacol) in inflammatory bowel disease. An open study.
    Faber SM, Korelitz BI.
    J Clin Gastroenterol; 1993 Oct 04; 17(3):213-8. PubMed ID: 8228082
    [Abstract] [Full Text] [Related]

  • 6. Treatment of Crohn's disease with peroral 5-aminosalicylic acid.
    Rasmussen SN, Binder V, Maier K, Bondesen S, Fischer C, Klotz U, Hansen SH, Hvidberg EF.
    Gastroenterology; 1983 Dec 04; 85(6):1350-3. PubMed ID: 6354827
    [Abstract] [Full Text] [Related]

  • 7. Bioavailability of single and multiple doses of enteric-coated mesalamine and sulphasalazine.
    Corey AE, Rose GM, Conklin JD.
    J Int Med Res; 1990 Dec 04; 18(6):441-53. PubMed ID: 1981363
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pericardial effusion during treatment with 5-aminosalicylic acid in a patient with Crohn's disease.
    Jenss H, Becker EW, Weber P.
    Am J Gastroenterol; 1990 Mar 04; 85(3):332-3. PubMed ID: 2309693
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group.
    Hanauer SB, Krawitt EL, Robinson M, Rick GG, Safdi MA.
    Am J Gastroenterol; 1993 Sep 04; 88(9):1343-51. PubMed ID: 8362827
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Hypersensitivity to 5-aminosalicylic acid. Value of desensitization by oral route].
    Lachaux A, Le Gall C, Loras-Duclaux I, Aboufadel A, Hermier M.
    Arch Pediatr; 1997 Feb 04; 4(2):144-6. PubMed ID: 9097825
    [Abstract] [Full Text] [Related]

  • 17. [Current salazosulfapyridine derivatives in the treatment of Crohn's disease].
    Belaiche J, Delwaide J, Louis E, Gast P.
    Rev Med Liege; 1991 Jan 04; 46(1):16-22. PubMed ID: 2011676
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Acute pancreatitis in Crohn's disease due to 5-ASA therapy.
    Radke M, Bartolomaeus G, Müller M, Richter I.
    J Pediatr Gastroenterol Nutr; 1993 Apr 04; 16(3):337-9. PubMed ID: 8492268
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.